Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 11/07/24
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle SocietyBusiness Wire • 10/01/24
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy StudiesZacks Investment Research • 09/19/24
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart TreatmentBenzinga • 09/19/24
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares DipInvestors Business Daily • 09/19/24
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 09/19/24
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern TimeBusiness Wire • 09/17/24
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 08/08/24
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to BuyZacks Investment Research • 07/17/24
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024Business Wire • 05/10/24
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 05/09/24
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 05/06/24
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesBusiness Wire • 04/23/24
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)Business Wire • 04/15/24
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionBusiness Wire • 03/28/24
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024Business Wire • 03/27/24
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024Business Wire • 03/05/24
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceBusiness Wire • 02/28/24